An article in the May 2, 2005, edition of BioWorld Today should have said that Amylin's Byetta was approved on the basis of a new drug application that included pivotal data showing that the drug met all primary glucose-control endpoints, including sustained 52-week reductions in hemoglobin A1c levels that averaged about 1.1 percent.

Editor's note: The correction has been made in BioWorld Online.